MACROGENICS INCMGNX
ASignal's systematic analysis rates MGNX as Neutral.
Reflects the latest available analysis · analyzed Oct 13, 2026
The case on MGNX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- High revenue growth (378.00% YoY)
- Strong cash position ($173.30M total cash)
- Current ratio of 2.96x indicates solid short-term liquidity
- Low debt-to-equity ratio (0.82x) relative to biotech peers
- Enterprise value to revenue of 0.56x suggests potential undervaluation
- Negative RSI (40.3) indicating weak momentum
- MACD below signal line with negative histogram
- Negative price momentum (-0.114)
- Negative gross, operating, and net margins
- Negative return on equity (-225.85%)
- Negative free cash flow (-$69.41M)
See the full verdict on MGNX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MGNX
Most investors never get a second opinion, let alone several. ASignal runs MGNX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.